Ensysce Biosciences Inc ENSC

$0.47 -0.04 (-7.93%)

Valuation

Market cap
9,943,000
Revenue TTM
$5,070,000
Net income TTM
$-10,180,000
PE ratio
0.00
Forward PE
—
Profit margin
-200.79%
Debt to equity
0.00

Trading

Volume
252,600
Avg volume
1,078,338
Day's range
$0.47 – $0.52
Shares out
19,457,000
Stochastic %K
0%
Beta
1.00
Analysts
Strong Sell
Price target
$5.12

Price

Company profile

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-do...

Show more

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company's lead product candidate is PF614, a TAAP oxycodone prodrug candidate for the treatment of severe or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection. It is also developing PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for attention deficit hyperactivity disorder; and PF9001 to treat opioid use disorder. Further, It develops neuroplastogenic therapies and psychedelic-derived molecules for severe chronic pain, particularly complex regional pain syndrome (CRPS). Ensysce Biosciences, Inc. was founded in 2003 and is based in La Jolla, California.

Industry
Biotechnology
Sector
Healthcare
Phone
858 263 4196
Website
https://www.ensysce.com
Address
7946 Ivanhoe Avenue, Suite 201, La Jolla, United States

Latest news

Stocktwits

VaporWaves Oct 24, 8:26 PM
ICMB keep this on watch for Monday/strong close. ICMB: -Fair value at $3.44.💎 -low float.💎 -clean/no dilution ever💎 -Positive cash flow/$1.44 cash per share.💎 -161 Million in asset.💎 -Possible Acquisition or merger catalyst.💎 $SOAR $FLYE $ENSC $VIOT :)1
0 replies
StockDreamin Oct 24, 2:18 PM
$ENSC looks like i wont be able to afford a Thanksgiving turkey!
0 replies
StockDreamin Oct 24, 12:51 AM
$ENSC R/S announcement soon to ruin your holidays!
0 replies
DeUrker Oct 23, 9:22 PM
$ENSC there is no plan…
0 replies
StockDreamin Oct 23, 6:21 PM
$ENSC What's the plan for compliance?
0 replies
Bernic88 Oct 23, 2:00 PM
$ENSC Currently overvalued, and as soon as (positive) data emerges, the next round of dilution will follow. If the data doesn't turn out as positive as expected, you surely know what that means.
0 replies
Bernic88 Oct 23, 11:02 AM
$ENSC My theory is that we will see a small run-up before the data is announced—a point at which I intend to sell. The release of the data will likely bring further dilution, as it is tied to the achievement of specific milestones. By the end of January at the latest, there will be another reverse split (RS), or at least an announcement of one. The risk of dilution here is enormous and is consistently linked to the attainment of certain results. So, buy the dip and sell into the rally while you still can.
0 replies
Bernic88 Oct 23, 5:35 AM
$ENSC Yes, very strange, why not $10 or $20 for such a game changer?
0 replies